- Home
- ACAD vs LAZ Comparison
ACAD vs LAZ Comparison
Compare ACAD & LAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- LAZ
- Stock Information
- Founded
- ACAD 1993
- LAZ 1848
- Country
- ACAD United States
- LAZ United States
- Employees
- ACAD N/A
- LAZ N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- LAZ Investment Managers
- Sector
- ACAD Health Care
- LAZ Finance
- Exchange
- ACAD Nasdaq
- LAZ Nasdaq
- Market Cap
- ACAD 3.8B
- LAZ 4.0B
- IPO Year
- ACAD 2004
- LAZ 2005
- Fundamental
- Price
- ACAD $20.98
- LAZ $52.18
- Analyst Decision
- ACAD Buy
- LAZ Hold
- Analyst Count
- ACAD 18
- LAZ 7
- Target Price
- ACAD $27.71
- LAZ $48.33
- AVG Volume (30 Days)
- ACAD 2.1M
- LAZ 974.4K
- Earning Date
- ACAD 08-05-2025
- LAZ 07-24-2025
- Dividend Yield
- ACAD N/A
- LAZ 3.85%
- EPS Growth
- ACAD N/A
- LAZ N/A
- EPS
- ACAD 1.37
- LAZ 2.87
- Revenue
- ACAD $996,283,000.00
- LAZ $2,939,019,000.00
- Revenue This Year
- ACAD $13.39
- LAZ N/A
- Revenue Next Year
- ACAD $10.59
- LAZ $15.92
- P/E Ratio
- ACAD $15.33
- LAZ $18.06
- Revenue Growth
- ACAD 22.42
- LAZ 7.18
- 52 Week Low
- ACAD $13.40
- LAZ $31.97
- 52 Week High
- ACAD $25.23
- LAZ $61.14
- Technical
- Relative Strength Index (RSI)
- ACAD 45.70
- LAZ 75.41
- Support Level
- ACAD $20.75
- LAZ $49.21
- Resistance Level
- ACAD $23.09
- LAZ $50.96
- Average True Range (ATR)
- ACAD 0.78
- LAZ 1.42
- MACD
- ACAD -0.20
- LAZ 0.44
- Stochastic Oscillator
- ACAD 9.83
- LAZ 97.27
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About LAZ Lazard Inc.
Lazard Inc has a storied history that can be traced back to 1848. The company's revenue is fairly evenly split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily driven by equities (over 80% of assets under management), has an international focus, and targets institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.